Open an account

Scribe Therapeutics

SCTX · NASDAQ

$19.81+$0.42 (+2.17%)TodayMarket closed ·
Prev close $19.39

About SCTX

Scribe Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Alameda, California. The company went IPO on 2026-07-24. Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The firm's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively.

Employees
0
Headquarters
Alameda, California
Listed
Jul 24, 2026
Sector
Health Care
Industry
Biotechnology
Website
scribetx.com

SCTX key statistics

Market cap
375.04M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
510.90K
Volume
203.67K
Open price
$19.64
High today
$21.37
Low today
$19.33
52 Week high
$39.60
52 Week low
$13.50

Scribe Therapeutics (SCTX) at a glance

As of Oct 20, 2026, Scribe Therapeutics (SCTX) shares are priced at $19.81, giving the company a market cap of 375.04M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.33 and $21.37. The current price is 2.5% above the day's low and 7.3% below its high.

Volume so far is 203.67K shares, below the average of 510.90K shares a day.

Over the past year Scribe Therapeutics has ranged from $13.50 to $39.60, and now sits 24% of the way up that range.

The average analyst price target is $58.14, 193.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $58.14
Low
$50.50
Now
$19.81
High
$63.00

SCTX news

  • Avi Kapoor

    Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

  • Chandrima Sanyal

    Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

  • Chandrima Sanyal

    Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

Similar companies

Companies in the same industry as Scribe Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.